💼 Business 5d ago · Quartz Staff

Hims & Hers stock jumps 14% after FDA schedules peptide compounding review

Quartz (QZ)
Global business news for the new economy
View Channel →
Hims & Hers stock jumps 14% after FDA schedules peptide compounding review
Source ↗ 👁 0 💬 0
The FDA will convene an outside panel in July to weigh compounding eligibility for 7 peptides, a category Hims & Hers has been positioning to enter

Comments (0)

Sign in to join the discussion

More Like This

Diales Group reports 43% jump in half-year operating profit
All News · 3h ago
Factory rebound lifts India’s private sector growth in April, PMI shows
All News · 3h ago
China’s Xpeng expects to start delivering ’flying’ cars in 2027
All News · 3h ago
Iran war boosts European logistics profits as shipping chaos persists
All News · 3h ago
Earnings call transcript: LG Display’s Q1 2026 shows OLED strength amid challenges
All News · 3h ago
BofA reiterates Buy on IBM stock, keeps $300 price target
All News · 3h ago